ClinicalTrials.gg
Active, not recruitingNCT05319873Updated May 11, 2026

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

A Phase 1/2 interventional study of Carboplatin and Docetaxel in Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 and Anatomic Stage IIB Breast Cancer AJCC v8, sponsored by Jonsson Comprehensive Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Jonsson Comprehensive Cancer Center · Phase 1/2, Interventional, and Treatment

How we know · 15 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Planned enrollment
75th of 94
18 · median 71
Started
2022
with 6 others
Phase 1/2
4 of 95
none open now
Primary completion
2027-04
later than 11 of 22 live
Registered
83rd of 95
by date

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 75th largest by planned enrollment of the 94 interventional ones that give a count, is one of 7 that started in 2022, is one of 4 in phase 1/2, reaches primary completion later than 11 of the 22 other live ones, and was the 83rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This phase Ib/II trial studies the side effects and best dose of ribociclib, tucatinib, and trastuzumab for the treatment of HER2 positive breast cancer that has spread to other parts of the body (metastatic), and then compares the effect of ribociclib, tucatinib, trastuzumab with or without fulvestrant to docetaxel, carboplatin, trastuzumab, and pertuzumab (standard of care) for the treatment of early stage breast cancer before surgery (neoadjuvant therapy). Ribociclib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Estrogen can cause the growth of breast tumor cells. Fulvestrant blocks the use of estrogen by the tumor cells. Chemotherapy drugs, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib, tucatinib, and trastuzumab with or without fulvestrant before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the safety of the combination of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer. (Phase 1 Dose Escalation Trial) II. To determine the recommended phase 2 dose of ribociclib when combined with tucatinib and trastuzumab. (Phase 1 Dose Escalation Trial) III. To assess the pathologic complete response (pCR). (Phase 2 Neoadjuvant Study)

SECONDARY OBJECTIVES:

I. To evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination. (Phase 1 Dose Escalation Trial) II. To assess the clinical objective response rate after 3 cycles via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. (Phase 1 Dose Escalation Trial) III. To assess the clinical objective response rate in the experimental arms. (Phase 2 Neoadjuvant Study) IV. To assess quality of life by evaluating toxicity burden using a quality of life (QOL)/patient-reported outcomes (PRO) questionnaire- the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) instrument. (Phase 2 Neoadjuvant Study) V. To assess the molecular changes in tumor biomarkers after 1 cycle of targeted therapy (anti-HER2, anti-estrogen, and CDK 4/6 directed therapy). (Phase 2 Neoadjuvant Study) VI. Pathological Assessment According to Residual Cancer Burden (RCB) Index at surgery. (Phase 2 Neoadjuvant Study)

EXPLORATORY OBJECTIVE:

I. To investigate potential serum and tumor predictive biomarkers to predict response to experimental therapy. (Phase 2 Neoadjuvant Study)

OUTLINE: This is a phase Ib, dose-escalation study of ribociclib followed by a phase II study.

PHASE Ib: Patients receive ribociclib orally (PO) once daily (QD) on days 1-21, tucatinib PO twice daily (BID) on days 1-28, and trastuzumab intravenously (IV) over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients with hormone receptor (HR) positive status are randomized to Arm A or Arm B. Patients with HR negative status are randomized to Arm B or Arm C.

ARM A: Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, trastuzumab IV over 30-90 minutes every 7 days and fulvestrant subcutaneously (SC) on days 1 and 15 of cycle 1 and day 1 of every subsequent cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive docetaxel IV over 1 hour on day 1, carboplatin IV on day 1, trastuzumab IV over 30-90 minutes on day 1, and pertuzumab IV over 1 hour on day 1. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

ARM C: Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed-up within 7 and 30 days.

03

Conditions studied

  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage IIA Breast Cancer AJCC v8
  • Anatomic Stage IIB Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • Anatomic Stage IIIC Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Invasive Breast Carcinoma
  • Locally Advanced HER2-Positive Breast Carcinoma
  • Metastatic HER2-Positive Breast Carcinoma
  • Prognostic Stage IB Breast Cancer AJCC v8
  • Prognostic Stage II Breast Cancer AJCC v8
  • Prognostic Stage IIA Breast Cancer AJCC v8
  • Prognostic Stage IIB Breast Cancer AJCC v8
  • Prognostic Stage III Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Prognostic Stage IV Breast Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PHASE IB AND II: Patients over age of 18
  • PHASE IB AND II: Available for confirmatory central testing. Results not required prior to enrollment.
  • PHASE IB AND II: (LVEF) >= 50% based on echocardiogram or multigated acquisition (MUGA).
  • PHASE IB AND II: count >= 100,000/mm\^3 (within 7 days before enrollment)

    • For Phase Ib only: Phase Ib allows for red blood cell transfusion, filgrastim (G-CSF), and hydration to meet eligibility requirements at the discretion of the investigator
  • PHASE IB AND II: >= 9.0 g/dL (within 7 days before enrollment)

    • For Phase Ib only: Phase Ib allows for red blood cell transfusion, G-CSF, and hydration to meet eligibility requirements at the discretion of the investigator
  • PHASE IB AND II: (ANC) >= 1500/mm\^3 (within 7 days before enrollment)

    • For Phase Ib only: Phase Ib allows for red blood cell transfusion, G-CSF, and hydration to meet eligibility requirements at the discretion of the investigator
  • PHASE IB AND II: >= 30 mL/min as calculated using the Cockcroft-Gault equation or Serum creatinine =\< 1.5 × (ULN) (within 7 days before enrollment)

    • For Phase Ib only: Phase Ib allows for red blood cell transfusion, G-CSF, and hydration to meet eligibility requirements at the discretion of the investigator
  • PHASE IB AND II: (ALT) \< 2.5 × ULN, except for patients with liver , who are only included if the ALT is \< 5 × ULN (within 7 days before enrollment)
  • PHASE IB AND II: Aspartate aminotransferase (AST) \< 2.5 × ULN, except for patients with liver metastasis, who are only included if the AST is \< 5 × ULN (within 7 days before enrollment)
  • PHASE IB AND II: Total =\< 1.5 x ULN. Participants with Gilbert's syndrome with a total bilirubin =\< 2.0 times ULN and direct bilirubin within normal limits are permitted (within 7 days before enrollment)
  • PHASE IB AND II: Serum Albumin >= 2.5 g/dL (within 7 days before enrollment)
  • PHASE IB AND II: (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =\< 1.5 × ULN (within 7 days before enrollment)
  • PHASE IB AND II: Potassium within normal limits or corrected to within normal limits prior to first dose
  • PHASE IB AND II: Magnesium within normal limits or corrected to within normal limits prior to first dose
  • PHASE IB AND II: Total calcium (corrected for serum albumin) within normal limits or corrected to within normal limits prior to first dose
  • PHASE IB AND II: Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • PHASE IB AND II: Patient can be premenopausal, perimenopausal, or at the time of study entry.

    • Premenopausal status is defined as either:

      • Patient had last menstrual period within the last 12 months, OR
      • If on tamoxifen or toremifene, plasma estradiol and follicle stimulating hormone (FSH) are in the premenopausal ranges according to central/local laboratory definition, OR
      • In case of therapy-induced amenorrhea, plasma estradiol and/or FSH are in the premenopausal ranges according to central/local laboratory definition

        • Perimenopausal status is defined as neither premenopausal nor postmenopausal
        • Postmenopausal is defined as not meeting premenopausal status
        • For pre-menopausal patients: Confirmed negative serum pregnancy test (beta-hCG) before starting study treatment or patient has had a hysterectomy. Male and female participants of reproductive/ must agree to use a highly effective form of or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug
  • PHASE IB AND II: Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Double barrier method of contraception. The following are considered adequate barrier methods of contraception, must use 2: diaphragm, condom (by the partner), sponge, or spermicide/spermicidal jelly.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking trial treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male partner sterilization (at least 6 months prior to randomization). For female patients on the trial the vasectomized male partner should be the sole partner for that patient. If vasectomy of the male partner is the highly effective method of contraception chosen, the success of the vasectomy should be medically confirmed according to local practice
    • Placement of an intrauterine device (IUD)
  • PHASE IB: Locally advanced/non-operable or metastatic HER2/neu amplified breast cancer, defined as 3+ by immunohistochemistry (IHC), or IHC 2+ and fluorescence in situ hybridization (FISH) + breast cancer
  • PHASE IB: Received 1 or more prior lines of HER2 directed therapy in the metastatic setting
  • PHASE IB: Recommended by the patient's treating oncologist to receive a tucatinib containing regimen as part of the next standard of care (SOC)
  • PHASE IB: (ECOG) performance status 0-2
  • PHASE IB: Measurable or non- per 1.1
  • PHASE IB: Based on screening contrast brain magnetic resonance imaging (MRI), patients must have one of the following:

    • No evidence of
    • Untreated brain metastases not needing immediate local therapy. For patients with untreated central nervous system (CNS) lesions > 2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment
    • Previously treated brain metastases

      • Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy, provided that there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator
      • Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if all of the following criteria are met:

        • Time since whole-brain radiotherapy (WBRT) is >= 21 days prior to first dose of treatment, time since stereotactic radiosurgery (SRS) is >= 7 days prior to first dose of treatment, or time since surgical resection is >= 28 days
        • Other sites of disease assessable by RECIST 1.1 are present
    • Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions
  • PHASE II: Operable HER2/neu amplified invasive breast cancer, defined as 3+ by IHC, or IHC 2+ and FISH +
  • PHASE II: Known Ki67 status
  • PHASE II: Previously untreated operable invasive carcinoma of the breast greater than 2.0 cm (cT2) in size based on imaging or physical exam or imaging. Patients with clinical node negative disease or clinical node (cN1/cN2) positive are allowed provided they are deemed to have operable disease at study entry
  • PHASE II: Patients with clinically involved lymph nodes should not have evidence of distant disease based on standard of care staging imaging prior to form (ICF) signature
  • PHASE II: Breast cancer suitable for mandatory baseline core biopsy
  • PHASE II: No prior systemic therapy or radiotherapy for currently-diagnosed invasive or non-invasive breast cancer
  • PHASE II: Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Exclusion criteria

Exclusion Criteria:

  • PHASE IB AND II: Concurrent therapy with any other non-protocol anti-cancer therapy
  • PHASE IB AND II: History of any other within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix
  • PHASE IB AND II: Proteinuria estimated by urine protein: creatinine ratio > 3.5 on a random urine sample
  • PHASE IB AND II: Uncontrolled arterial hypertension despite optimal medical management
  • PHASE IB AND II: Patient has known active virus (HBV) or virus (HCV), or (HIV) infection (testing is not mandatory, unless required by local regulation)
  • PHASE IB AND II: Uncontrolled infection; active, clinically serious infections (> [CTCAE] grade 2)
  • PHASE IB AND II: , uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following:

    • History of documented myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry
    • Documented cardiomyopathy
    • (LVEF) \< 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
    • Long syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

      • Risk factors for Torsades de Pointe (TdP) including uncorrected hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
      • Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g., within 5 half-lives or 7 days prior to starting study drug)
      • Inability to determine the corrected QT using Fridericia's formula (QTcF) interval
      • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
      • Systolic blood pressure (SBP) > 160 or \< 90 mmHg
  • PHASE IB AND II: Congestive heart failure > (NYHA) class 2
  • PHASE IB AND II: History of baseline QT prolongation > 450 msec
  • PHASE IB AND II: Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
  • PHASE IB AND II: Myocardial infarction less than 6 months before start of test drug
  • PHASE IB AND II: Anti-arrhythmic therapy (beta blockers or digoxin are permitted)
  • PHASE IB AND II: Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication.
  • PHASE IB AND II: Participants receiving anticoagulation therapy are not allowed
  • PHASE IB AND II: Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event >= CTCAE Grade 3 within 4 weeks of start of study medication
  • PHASE IB AND II: Non-healing wound or ulcer
  • PHASE IB AND II: History of, or current disease (other than Hashimoto's thyroiditis with normal thyroid stimulating hormone [TSH])
  • PHASE IB AND II: Major surgical procedure or significant traumatic injury (as judged by the investigator) within 28 days before start of study medication, open within 7 days before start of study medication
  • PHASE IB AND II: Unable to swallow pills or has significant gastrointestinal disease which would preclude the adequate oral absorption of medications
  • PHASE IB AND II: Patients with seizure disorder requiring medication
  • PHASE IB AND II: Known to any of the study drugs, study drug classes, or in the formulation
  • PHASE IB AND II: Systemic continuous therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed. Patients may be using topical or inhaled corticosteroids. Previous corticosteroid therapy must be stopped or reduced to the allowed dose at least 7 days prior to the first study drug administration. If a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the consent document
  • PHASE IB AND II: History of having received an allogeneic bone marrow or organ transplant
  • PHASE IB AND II: Chronic oxygen therapy
  • PHASE IB AND II: Use of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor or use of a strong or CYP2C8 inducer within 5 days prior to the first dose of study treatment
  • PHASE IB: Early stage (curable) breast cancer
  • PHASE IB: Based on screening brain MRI, patients must not have any of the following:

    • Any untreated brain lesions > 2.0 cm in size, unless discussed with medical monitor and approval for enrollment is given
    • Ongoing use of systemic corticosteroids for control of symptoms of at a total daily dose of > 2 mg of dexamethasone (or equivalent). However, patients on a chronic stable dose of =\< 2 mg total daily of dexamethasone (or equivalent) may be eligible with discussion and approval by the medical monitor
    • Any brain lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related edema may pose risk to patient (e.g. brain stem lesions). Patients who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under CNS inclusion criteria
  • PHASE IB: Known or suspected (LMD) as documented by the investigator
  • PHASE IN: Have poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain metastases notwithstanding CNS-directed therapy
  • PHASE II: breast cancer (local spread to axillary or internal mammary lymph nodes is permitted)
  • PHASE II: Current therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), gonadotrophin-releasing hormone (GNRH) agonist/antagonist, either for osteoporosis or prevention of breast cancer. Subjects must have discontinued therapies for at least 28 days prior to first baseline biopsy
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Phase Ib (ribociclib, tucatinib, trastuzumab)

    Patients receive ribociclib PO QD on days 1-21, tucatinib PO BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

    Other: Quality-of-Life Assessment · Drug: Ribociclib · Biological: Trastuzumab · Drug: Tucatinib

  • Experimental
    Phase II, Arm C (ribociclib, tucatinib, trastuzumab)

    Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Other: Quality-of-Life Assessment · Drug: Ribociclib · Biological: Trastuzumab · Drug: Tucatinib

  • Experimental
    Phase II,Arm A(ribociclib,tucatinib, trastuzumab, fulvestrant)

    Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, trastuzumab IV over 30-90 minutes every 7 days and fulvestrant subcutaneously (SC) on days 1 and 15 of cycle 1 and day 1 of every subsequent cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Fulvestrant · Drug: Ribociclib · Biological: Trastuzumab · Drug: Tucatinib

  • Active comparator
    Phase II,Arm B(docetaxel,carboplatin,trastuzumab,pertuzumab)

    Patients receive docetaxel IV over 1 hour on day 1, carboplatin IV on day 1, trastuzumab IV over 30-90 minutes on day 1, and pertuzumab IV over 1 hour on day 1. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Carboplatin · Drug: Docetaxel · Biological: Pertuzumab · Other: Quality-of-Life Assessment · Biological: Trastuzumab

Interventions

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • Given IV

    Also known as: Docecad, RP56976, Taxotere, Taxotere Injection Concentrate

  • Given SC

    Also known as: Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238

  • BiologicalPertuzumab

    Given IV

    Also known as: 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451

  • OtherQuality-of-Life Assessment

    Ancillary Studies

    Also known as: Quality of Life Assessment

  • Given PO

    Also known as: Kisqali, LEE-011, LEE011

  • BiologicalTrastuzumab

    Given IV

    Also known as: ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera

  • Given PO

    Also known as: ARRY-380, Irbinitinib, ONT-380, Tukysa

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) (Phase Ib)

    Defined as the highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing level.

    Time frame: During the first cycle of treatment (1 cycle = 28 days)

  2. Pathologic complete response (pCR) (Phase II)

    Defined as no invasive tumor in the breast or lymph nodes at the time of surgery. Response evaluable participants are defined as participants who are randomized and have receive at least one cycle of protocol therapy. The pCR rate is defined as percentage of randomized patients with a pCR in each of the treatment arms.The estimated pCR rate (and 95% confidence interval \[CIs\]) will be calculated for each experimental arm and compared to the corresponding control arm using the Cochran-Mantel-Haenszel x\^2 test, with a two-sided significance level of 5%. Absolute differences in pCR rate between study arms will be calculated, along with 95% exact confidence intervals. This will be stratified according to hormone receptor (HR) status Multivariate logistic regression will be used to control for important baseline characteristics and odds ratios with corresponding CIs will be calculated.

    Time frame: Up to 30 days after last treatment dose

Secondary outcomes

  1. Clinical objective response rate (ORR) (Phase IB and II)

    ORR will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 using caliper measurements. A responder is defined as any participant who exhibits a complete response (CR) or partial response (PR). The clinical response rate is estimated as the total number of CRs and PRs divided by the total number of participants randomized.The estimated ORR rate (and 95% CIs) will be calculated for each treatment arm and compared using the Cochran-Mantel-Haenszel x\^2 test, with a two-sided significance level of 5%. Absolute differences in pCR rate between study arms will be calculated, along with 95% exact confidence intervals. This will be stratified according to HR status. Multivariate logistic regression will be used to control for important baseline characteristics and odds ratios with corresponding CIs will be calculated.

    Time frame: Up to 30 days after last treatment dose

  2. Evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination with tucatinib and trastuzumab. (Phase 1b): Area Under Curve (AUC)

    The pharmacokinetic (PK) parameter - area under the plasma concentration-time curve (AUC) will be determined for ribociclib and tucatinib in all Phase 1b participants.

    Time frame: Pre-infusion and 1, 2, 3, and 6 hours after the start of the infusion

  3. Evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination with tucatinib and trastuzumab. (Phase 1b): Elimination half-life (t½)

    The pharmacokinetic (PK) parameter - Elimination half-life (t½) will be determined for for ribociclib and tucatinib in all Phase 1b participants.

    Time frame: Pre-infusion and 1, 2, 3, and 6 hours after the start of the infusion

  4. Evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination with tucatinib and trastuzumab. (Phase 1b): Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) will be determined for for ribociclib and tucatinib in all Phase 1b participants.

    Time frame: Pre-infusion and 1, 2, 3, and 6 hours after the start of the infusion

  5. Evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination with tucatinib and trastuzumab. (Phase 1b): Minimum plasma concentration

    Minimum plasma concentration will be determined for ribociclib and tucatinib in all Phase 1b participants.

    Time frame: Pre-infusion and 1, 2, 3, and 6 hours after the start of the infusion

  6. Evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination with tucatinib and trastuzumab. (Phase 1b): Time when Cmax occurs (Tmax)

    Time when Cmax occurs (Tmax) will be determined for ribociclib and tucatinib in all Phase 1b participants.

    Time frame: Pre-infusion and 1, 2, 3, and 6 hours after the start of the infusion

  7. Evaluate the pharmacokinetics of ribociclib and tucatinib when given in combination with tucatinib and trastuzumab. (Phase 1b): Average plasma concentration at steady state (Cavg)

    Average plasma concentration at steady state (Cavg) will be determined for ribociclib and tucatinib in all Phase 1b participants.

    Time frame: Pre-infusion and 1, 2, 3, and 6 hours after the start of the infusion

  8. Quality of life (QOL) (Phase II)

    The EPRTC QLQ-C30 (European Organization for the Research and Treatment of Cancer- Quality of Life questionnaire) is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / Quality of Life (QoL) scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Up to 7 days after last treatment dose

  9. Measure the gene expression and/or biomarker changes that may be correlated with or predict biological, clinical, and pathologic response (Phase II)

    Primary analysis of these molecular changes will include a linear model with treatment and hormone receptor status fixed effects. Separate analyses for change after 1 cycle and all cycles will be performed and compared to baseline levels. Serum and tumor biomarker analyses, including but not limited to on treatment tumor CD45 expression and germline IL6 promoter genotyping will be correlated with clinical outcomes and important clinical characteristics. Absolute change in Ki67 and cell cycle arrest rate (defined as a Ki67 of =\< 2.7%) will be analyzed separately.

    Time frame: Up to 30 days after last treatment dose

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2027, 59 months after the start.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 59 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Apr 8, 2022
StartActual
Apr 7, 2022
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2028
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05319873
Collaborators
Seagen Inc., Novartis
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Apr 7, 2022
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
May 11, 2026

Study contacts

Nicholas P McAndrew
principal investigator · UCLA / Jonsson Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fulvestrant · Ribociclib · Tucatinib

Start the discussion